A decrease in platelet activity was greater in the ACS group in comparison to the CHD group since ticagrelor is a more potent P2Y12 antagonist than clopidogrel, although differences were not significant for some activation indexes (predominantly for the most powerful agonist—TRAP 10 μM + Epinephrine, 20 μM) (Figure 1 and Table 2). This evidence concerns the gene P2RY12 and coronary artery disorder.